carbon signals. Of particular interest was the establishment of the linkage between the two monomeric halves of the molecule and determination of the location of the phenolic hydroxyls.
Crisamicin A (CRS-A) a novel isochromanequinone antibiotic produced by Micromonospora purpureochromogenes subsp. halotolerans,1 '^is a symmetrical dimeric molecule, like actinorhodin, 3) and bears structural similarities to the antibiotics nanaomycin D,4) kalafungin,5) medermycin6) and mederrhodin A6) (Fig. 1 ). Preliminary investigations indicated that the CRS-A molecule possessed one of two possible structures, (Fig. 2) , with 1 being favored based on chemical data.
2) The two alternative structures differ in the location of the phenolic hydroxyl groups and in the position of the linkage bond between the two monomers. An examination of these possible structures suggests that CRS-Ais formed from acetate via the polyketide pathway as are other membersof this class of antibiotics. In order to distinguish between structures 1 and 2 and to allow for the unambiguous assignment of the 13C NMRspectrum, the biosynthesis of CRS-Awas examined by 13C-labeled C-l and C-2 acetate studies. The present paper describes the results of such experiments leading to 1 as the correct structure for CRS-A. TLC and Column Chromatography Samples were analyzed by TLC on Silica Gel-60 F-254 (EM Reagents, Darmstadt, FRG) with an adsorbent thickness of 250 jum. TLCplates were developed in CHC13-MeOH-acetic acid (95 : 5 : 1) and compounds of interest were visualized under UVlight.
Column chromatography was conducted on Kieselgel 60, 70~230 mesh (EM Reagents, Darmstadt, FRG) slurried in CHC13. Samples were loaded in CHC13 and eluted with CHC13 -MeOH(99 : 1).
HPLC
HPLCwas performed on a Waters LC system, equipped with a Model 680 Automated Gradient Controller, two Model 510 pumps and a Model 490 Programmable Multiwavelength Detector. Separations were carried out as described earlier.P reparation of Labeled CRS-A Fermentations of labeled CRS-Awere carried out as described previously,1} except that 600 ml of the production medium was used in 2,000-ml baffled flasks (Catalog No. 2542-02000, Bellco Glass Inc., Vineland, New Jersey). Production flasks were inoculated with 30 ml (5%) of the inoculum culture and incubated at 28°C on a Model G-53 Rotary Shaker (New Brunswick Scientific Co., Edison, New Jersey) operated at 200 rpm.
CRS-Atiters were monitored in the fermentation broths daily by HPLCassay by extraction of an aliquot of the broth as described previously.L abeled acetate was added whenassays indicated the onset of antibiotic production (approximately 60 hours). Sodium acetate labeled with 13C at the C-l or the C-2 position was dissolved in distilled water (900 mg/50 ml) and 25 ml of this solution was added to each of two production flasks to give a final concentration of 750 mg/liter of labeled sodium acetate. The fermentations were harvested when CRS-Atiters began to decline, at approximately 170 hours. NOV. 1988 Whole broths (ca. 1.0 liter) were extracted twice with EtOAc at neutral pH. The combined extracts were taken to dryness, and triturated with hexane to remove the oily material and to give ca 700 mg of crude product which contains ca. 300mg of CRS-A. The 13C enriched CRS-Awas purified by column chromatography on silica gel and analyzed by TLC (Rf 0.48) and by HPLCcomparing with standard CRS-A described previously.1}
Preparation of CRS-ADiacetate The 13C enriched CRS-A (50 mg) was added with stirring to acetic anhydride (50 ml) at room temperature. A drop of concentrated sulfuric acid was added as a catalyst. Several small pieces of ice were added and the reaction mixture was stirred for 15 minutes. After this time more ice was added to decomposethe excess acetic anhydride. Twovolumes of water were added, and the reaction mixture was extracted three times with an equal volume of CHC13.The pooled CHC18extract was washed three times with four volumes of water. The organic layer was recovered, dried over Na2SO4,and taken to dryness in vacuo to give 45 mg of crude product, 40 mg of which on purification on silica gel chromatography gave CRS-Adiacetate (28 mg). The eluting solvent was CHC13-MeOH(99 : 1). Formation of the diacetate derivative was confirmed by NMR(loss of signal at ll.88 ppm from phenolic hydroxyl, appearance of signal at 2.50 ppm due to a methyl group), IR (KBr pellet; CRS-A, 1759, 1650, 1624 cm"1; CRS-A diacetate, 1783, 1668, 1605 cm"1) and mass spectrometry (fast atom bombardment (FAB) negative ion mode, m/z 683 (M-H)~for hydroquinone form; FAB positive ion mode, m/z 685 (M+H)+ for hydroquinone form), as well as by TLC (Rf; CRS-A 0.48; CRS-A diacetate 0.54).
Results and Discussions
The natural abundance 13C NMRspectrum for CRS-A (Fig. 3A) shows the presence of 16 signals as expected from a symmetrical dimeric molecule with the molecular formula C32H22O12.2)Spectra of [1-13C] and [2-13C] acetate enriched CRS-A are presented in Figs. 3B and 3C, respectively, each of which show the enrichment of eight carbons with no carbon being enriched by the same acetate precursor. The presence of eight enhanced signals in each spectrum thus suggests the alternate labeling pattern anticipated from a polyketide derived compound.
Some peak assignments could be made based on chemical shift data, peak multiplicities and offresonance decoupling and single bond 1H-18C coupling.7>8) Confirmation and differentiation of peak assignments was from labeling patterns, peak intensities and chemical shifts observed from the CRS-A diacetate derivatives (Fig. 4) . Reference was also made to the published spectra for juglone9) and for other isochromanequinone antibiotics.10~14) Enrichment factors for the C-l and C-2 acetate labeled compoundswere calculated for CRS-Aacetate, using the acetate methyl carbon to normalize peak heights. Previously published enrichment factors for CRS-A15) were in error due to improper normalization of peak height data. The chemical shifts, peak multiplicities, and enrichment factors for CRS-Aand CRS-Aacetate are shown in Table 1 .
In addition to demonstrating the biosynthetic origin of the CRS-Amolecule, these data confirm 1 as the correct structure (Fig. 2) . In the CRS-A spectrum (Fig. 3) the labeling of the peaks at 118.0 and 123.0 ppm by C-l of acetate and assignment to aromatic carbons bearing free protons, places these carbons at positions C-9 and C-7 respectively.^The phenolic carbon is observed to be enriched by C-2 of acetate in the CRS-A acetate spectrum (peak at 148.7 ppm in Fig. 4) thus placing it at C-6 of the CRS-A molecule. Also, the down field shift observed for the C-5 quinone carbonyl (chemical shift 186.8 ppm) relative to the C-10 carbonyl (181.8 ppm) is indicative of hydrogen bonding of C-5 quinone carbonyl to the C-6 phenolic hydroxyl. The linkage point between the two monomers can thus be located at C-8, meta to the phenolic hydroxyl by the observation (under off-resonance decoupling) of a singlet for C-8 and doublets for C-l and C-9, showing C-8 to be the carbon atom substituted by the adjoining monomer. Taken together, these data confirm 1 as the correct structure for CRS-A.
Biosynthetic studies on the isochromanequinone antibiotics have been reviewed by Floss.16) CRS-Awas labeled by C-l and C-2 of acetate in the manner expected for biosynthesis via the polyketide pathway, and is in agreement with the labeling patterns seen for the other isochromanequinone antibiotics (Fig. 5) .
A proposed biosynthetic pathway of CRS-Awould include the following steps (not necessarily in the order listed) :
1) Synthesis of the polyketide backbone of the monomerby head-to-tail condensation of acetate 2) Oxygenation (at C-5 and C-6) and deoxygenation (at C-7 and C-9) reactions; 3) Cyclization of the backbone to form the ring system; and, 4) Dimerization to form the completed molecule. The labeling of equivalent positions in each monomerargues for dimerization, as opposed to cyclization of a single 32 carbon monomer,to form two ring systems.
The location of the phenolic hydroxyl group in CRS-A is of particular interest. In all the previously described isochromanequinone antibiotics, the C-9 position is substituted with, oxygen, either as phenolic hydroxyl, or as carbonyl oxygen. CRS-Atherefore represents the first compoundof this group in which the C-9 has no substitution. The polyketide backbone from which the molecule is synthesized would carry oxygen at this position from the carboxyl group of acetate. Therefore, some mechanismfor the removal of this oxygen must exist in the crisamicin producing strain. Also, the existence of an oxygen atom at position C-6 is of interest, as this is the position similarly modified in the formation of the hybrid antibiotics, mederrhodins A and B, from its parent compound, medermycin6'17) (Fig. 1) . In these studies, cloned act genes, which led to mederrhodin synthesis when transformed into the medermycinsynthesizing organism, were able to complementclass U act mutants of Streptomyces coelicolor. These mutants are blocked in the reaction leading to the hydroxylation of actinorhodin at the carbon atom equivalent to C-6 of CRS-A.In addition, studies on the genetics of actinorhodin biosynthesis,18) and the cloning of genes for the complete pathway for biosynthesis of this compound19) have stimulated interest in this group of compounds.
